all report title image
  • Published On : Sep 2020
  • Code : CMI70
  • Industry : Medical Devices
  • Pages : 304
  • Formats :

Therapeutic applications of radiopharmaceuticals include treatment of specific cancers under specific conditions. For instance, Yttrium-90 Ibritumomab Tiuxetan (Zevalin, Spectrum Pharmaceuticals) is indicated for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL) and treatment of previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy. Also, Radium-223 dichloride (Xofigo, Bayer HealthCare Pharmaceuticals Inc.) is indicated for the treatment of patients with castration-resistant prostate cancer, and symptomatic bone metastases and no known visceral metastatic disease. Hence, increasing prevalence of cancer is expected to drive the market growth over the forecast period. According to the Cancer Research UK, in 2014, around 357,000 new cancer cases were diagnosed in the U.K., accounting for 980 cases diagnosed per day. Breast, prostate, lung, and bowel cancers together accounted for over 53% of the total cancers in the U.K.

Market Dynamics

Market players are focusing on various inorganic growth strategies such as collaboration and partnership agreements in order to expand their market presence, which is expected to boost growth of the global radiopharmaceuticals in nuclear medicine market over the forecast period. For instance, in October 2018, Cardinal Health Inc. and Telix Pharmaceuticals Inc., a subsidiary of Telix Pharmaceuticals Limited, entered into a distribution agreement. As per the agreement, Cardinal Health will both distribute the 69Ga-PSMA Kit and prepare unit doses of 68Ga-PSMA delivered as an investigational product for use in qualified investigator-sponsored clinical trials, including Telix-sponsored clinical trials.

Similarly, in January 2019, Progenics Pharmaceuticals, Inc. and Curium Pharma entered into an agreement to develop and commercialize PyL in Europe. PyL is Progenics’ PSMA-targeted small molecule PET/CT imaging agent, designed to visualize prostate cancer, which is in Phase 3 development.      

Key features of the study:

  • This report provides in-depth analysis of the global radiopharmaceuticals in nuclear medicine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company, Bracco S.p.A., Bayer AG, Advanced Accelerator Applications, S.A., Eli Lilly and Company, Nihon Medi-Physics. Co. Ltd., FUJIFILM Toyama Chemical Co., Ltd., Jubilant Life Sciences Ltd., Samyoung Unitech, and DuChemBio, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market.

Detailed Segmentation:

  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type:
    • Diagnostic Nuclear Medicine
      • SPECT Radiopharmaceuticals
      • PET Radiopharmaceuticals
    • Therapeutic Nuclear Medicine
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Region:
    • North America
      • By Product Type:
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals
          • PET Radiopharmaceuticals
        • Therapeutic Nuclear Medicine
      • By Application
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals
          • PET Radiopharmaceuticals
        • Therapeutic Nuclear Medicine
      • By Application
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals
          • PET Radiopharmaceuticals
        • Therapeutic Nuclear Medicine
      • By Application
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals
          • PET Radiopharmaceuticals
        • Therapeutic Nuclear Medicine
      • By Application
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals
          • PET Radiopharmaceuticals
        • Therapeutic Nuclear Medicine
      • By Application
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers  
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals
          • PET Radiopharmaceuticals
        • Therapeutic Nuclear Medicine
      • By Application
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Progenics Pharmaceuticals, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • NorthStar Medical Radioisotopes LLC
    • Curium Pharma
    • Life Molecular Imaging
    • Lantheus Holdings, Inc.
    • Cardinal Health, Inc.
    • General Electric Company
    • Bracco S.p.A.
    • Bayer AG
    • Advanced Accelerator Applications, S.A.
    • Eli Lilly and Company
    • Nihon Medi-Physics. Co. Ltd.
    • FUJIFILM Toyama Chemical Co., Ltd.
    • Jubilant Life Sciences Ltd.
    • Samyoung Unitech
    • DuChemBio, Inc.

“*” marked represents similar segmentation in other categories in the respective section.    

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Radiopharmaceuticals in Nuclear Medicine Market – Impact of Coronavirus (Covid-19) Pandemic
    • Pre-COVID 19 Market Situation
    • Government Initiatives
    • Guidance For Nuclear Medicine Departments
  5. Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Diagnostic Nuclear Medicine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • SPECT Radiopharmaceuticals
        • PET Radiopharmaceuticals
    • Therapeutic Nuclear Medicine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Radiopharmaceuticals in Nuclear Medicine Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Cardiology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Neurology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Endocrinology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Radiopharmaceuticals in Nuclear Medicine Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Diagnostic Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Radiopharmaceuticals in Nuclear Medicine Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Progenics Pharmaceuticals, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • NorthStar Medical Radioisotopes LLC
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Curium Pharma
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Life Molecular Imaging
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lantheus Holdings, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cardinal Health, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • General Electric Company
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bracco S.p.A.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Advanced Accelerator Applications, S.A.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Nihon Medi-Physics. Co. Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • FUJIFILM Toyama Chemical Co., Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Jubilant Life Sciences Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Samyoung Unitech
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • DuChemBio, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 56 market data tables and 50 figures on "Radiopharmaceuticals in Nuclear Medicine Market” - Global forecast to 2027

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo